Photo of Professor Gregory Lip

Professor Gregory Lip MD FRCP (London Edinburgh Glasgow) DFM FACC FESC FEHRA

Price-Evans Chair of Cardiovascular Medicine, University of Liverpool, United Kingdom; Distinguished Professor, Aalborg University, Denmark Cardiovascular & Metabolic Medicine


Personal Statement

Professor Lip, MD, is Price-Evans Chair of Cardiovascular Medicine, at the University of Liverpool, UK – and Director of the Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital. He is also Distinguished Professor at Aalborg University, Denmark; and Adjunct Professor at Seoul National University and Yonsei University, Seoul, Korea.
Half of his time is spent as a clinical cardiologist, including outpatient clinics (leading large atrial fibrillation and hypertension specialist services) and acute cardiology.

Professor Lip has had a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification. The CHA2DS2-VASc and HAS-BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines.
His introduction of the ABC (Atrial fibrillation Better Care) pathway (2017/PMID:28960189) streamlines AF patient management ('Easy as ABC ...'). The ABC pathway reduces mortality/hospitalisation/adverse outcomes (PMID:30551910, 30659810), and was tested in the mAFA-II clinical trial (PMID:32241367). ABC Pathway is now recommended in guidelines: CHEST guidelines from the American College of Chest Physicians (2018; PMID:30144419); Korean Heart Rhythm Society (PMID:30403013); ESC consensus papers (PMID:30882141,31976747); and the new 2020 ESC Guidelines (PMID:32860505).

In 2014, Professor Lip was ranked by Expertscape ( as the world's leading experts in the understanding and treatment of AF [].

His current group’s research interests are broad, ranging from epidemiology to pathophysiology, translational research, clinical risk assessment and trajectories of risk, patient management pathways, and applied health research. He is passionate about using ‘big data’ and epidemiological observations to generate hypotheses and to inform clinical studies that help improve the management of common cardiovascular conditions, such as atrial fibrillation, hypertension and thrombosis. This ‘big data’ work is often in collaboration with an extensive global network of friends and collaborators, including those in Denmark, France, the Balkans, Taiwan, Korea and Japan, sharing a common goal in ‘research without boundaries’ in relation to epidemiology and clinical studies.

Professor Lip was on the writing committee for various international guidelines, including the American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from the European Society of Cardiology (ESC) or EHRA. Specifically, he was also on the writing committees of the ESC Guidelines on Atrial Fibrillation (2010, 2012, 2020), the 2012 ESC Guidelines on Heart Failure, and the 2014 NICE guidelines on AF. He was Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012), and Chair of the 2018 ACCP Guidelines on antithrombotic therapy for AF.

Professor Lip has acted as senior/section editor for major international textbooks and at senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies); Europace (Associate Editor); and Circulation (Guest Editor).